L'agenzia del farmaco degli Stati Uniti ha approvato il primo vaccino antinfluenzale a mRNA per gli anziani.

The clearance paves the way for the first preventive flu shot based on mRNA technology and completes a dramatic regulatory turnaround.

The first mRNA-based flu shot to be approved by the Food and Drug Administration will be ready for the upcoming flu season. Moderna, the vaccine's maker

Agência havia rejeitado análise inicial por considerar testes insuficientes

The vaccine, developed by Moderna, is approved for adults ages 50 to 64 and those 65 and older, who face the highest risk of severe illness.